Oxford BioDynamics (LON:OBD – Get Free Report) issued its quarterly earnings results on Tuesday. The biotechnology company reported GBX (0.10) EPS for the quarter, Digital Look Earnings reports. Oxford BioDynamics had a negative net margin of 825.61% and a negative return on equity of 451.74%.
Oxford BioDynamics Stock Performance
LON OBD traded up GBX 0.01 on Thursday, reaching GBX 0.10. The stock had a trading volume of 58,510,266 shares, compared to its average volume of 16,621,342. The company has a debt-to-equity ratio of 131.61, a current ratio of 2.01 and a quick ratio of 2.80. The firm has a fifty day moving average of GBX 0.18 and a two-hundred day moving average of GBX 0.22. Oxford BioDynamics has a 1-year low of GBX 0.08 and a 1-year high of GBX 0.78. The company has a market cap of £4.29 million, a P/E ratio of -0.12 and a beta of 0.42.
Oxford BioDynamics Company Profile
Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.
In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.
Read More
- Five stocks we like better than Oxford BioDynamics
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for Oxford BioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.
